

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

December 11, 2025

Consolidated Financial Results for the Fiscal Year Ended October 31, 2025 (Under Japanese GAAP)



Company name: CellSource Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4880
 URL: <https://www.cellsources.co.jp/>
 Representative: Masayuki Yamakawa, Representative Director and CEO
 Inquiries: Tomohiro Iga, Executive Officer and General Manager of Corporate Division
 Telephone: +81-3-6455-5308
 Scheduled date of annual general meeting of shareholders: January 28, 2026
 Scheduled date to commence dividend payments: January 13, 2026
 Scheduled date to file annual securities report: January 27, 2026
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Fiscal Year Ended October 31, 2025 (from November 1, 2024 to October 31, 2025)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
October 31, 2025	3,711	—	166	—	167	—	10	—
October 31, 2024	—	—	—	—	—	—	—	—

Note: Comprehensive income Fiscal year ended October 31, 2025: ¥6 million [—%]
 Fiscal year ended October 31, 2024: ¥— million [—%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
Fiscal year ended	Yen	Yen	%	%	%
October 31, 2025	0.54	0.54	0.2	2.4	4.5
October 31, 2024	—	—	—	—	—

Reference: Share of profit (loss) of entities accounted for using equity method
 Fiscal year ended October 31, 2025: ¥— million
 Fiscal year ended October 31, 2024: ¥— million

Note: The Company has prepared consolidated financial statements from the fiscal year ended October 31, 2025. Therefore, figures and year-on-year changes for the fiscal year ended October 31, 2024 as well as year-on-year changes for the fiscal year ended October 31, 2025 are not stated.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
October 31, 2025	7,023	6,016	84.0	297.80
October 31, 2024	—	—	—	—

Reference: Equity
 As of October 31, 2025: ¥5,902 million
 As of October 31, 2024: ¥— million

Note: The Company has prepared consolidated financial statements from the fiscal year ended October 31, 2025. Therefore, figures as of October 31, 2024 are not stated.

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
October 31, 2025	333	(3)	61	4,711
October 31, 2024	—	—	—	—

Note: The Company has prepared consolidated financial statements from the fiscal year ended October 31, 2025. Therefore, figures for the fiscal year ended October 31, 2024 are not stated.

2. Cash Dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended October 31, 2024	—	0.00	—	5.00	5.00	99	—	—
Fiscal year ended October 31, 2025	—	0.00	—	5.00	5.00	99	929.4	1.7
Fiscal year ending October 31, 2026 (Forecast)	—	0.00	—	0.00	0.00		—	

Note: The Company has prepared consolidated financial statements from the fiscal year ended October 31, 2025. Therefore, payout ratio and ratio of dividends to net assets for the fiscal year ended October 31, 2024 are not stated.

3. Consolidated Financial Result Forecasts for the Fiscal Year Ending October 31, 2026 (from November 1, 2025 to October 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	3,418	(7.9)	(170)	—	(164)	—	(136)	—	(6.90)

*** Notes**

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (Hybrid Medical Co., Ltd.)

Excluded: —

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

(ii) Changes in accounting policies due to reasons other than (i): None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(3) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of October 31, 2025	19,819,962 shares
As of October 31, 2024	19,806,100 shares

(ii) Number of treasury shares at the end of the period

As of October 31, 2025	580 shares
As of October 31, 2024	580 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended October 31, 2025	19,813,981 shares
Fiscal year ended October 31, 2024	19,802,005 shares

* Financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts and other special matters

(Cautionary note on forward-looking statements, etc.)

The earnings forecasts and forward-looking statements described herein are based on information currently available to the Company and certain assumptions deemed reasonable, and are not intended to be a promise by the Company to achieve them. As such, actual results may differ significantly from these forecasts due to a wide range of factors.

(Method of obtaining the supplementary material on financial results and details of the financial results briefing)
The Company plans to hold a briefing online for investors and analysts on Thursday, December 11, 2025.

3. Consolidated Financial Statements and Principal Notes

(1) Consolidated Balance Sheets

(Thousands of yen)

As of October 31, 2025	
Assets	
Current assets	
Cash and deposits	4,711,820
Accounts receivable - trade	337,998
Merchandise and finished goods	89,646
Work in process	39,814
Raw materials and supplies	136,721
Other	176,927
Allowance for doubtful accounts	(5,329)
Total current assets	5,487,599
Non-current assets	
Property, plant and equipment	
Buildings, net	702,019
Tools, furniture and fixtures, net	234,029
Construction in progress	2,200
Other, net	50,505
Total property, plant and equipment	988,754
Intangible assets	
Other	56,393
Total intangible assets	56,393
Investments and other assets	
Investment securities	110,722
Leasehold and guarantee deposits	288,261
Deferred tax assets	73,469
Other	18,933
Allowance for doubtful accounts	(165)
Total investments and other assets	491,221
Total non-current assets	1,536,369
Total assets	7,023,969

(Thousands of yen)

As of October 31, 2025

Liabilities	
Current liabilities	
Accounts payable - trade	61,890
Lease liabilities	20,890
Accounts payable - other	70,702
Income taxes payable	28,348
Provision for bonuses	63,136
Provision for bonuses for directors (and other officers)	4,221
Provision for loss on orders received	1,923
Provision for share-based payments	10,412
Provision for loss on contract	36,499
Other	144,813
Total current liabilities	442,839
Non-current liabilities	
Lease liabilities	35,829
Asset retirement obligations	301,457
Provision for loss on contract	227,016
Total non-current liabilities	564,303
Total liabilities	1,007,142
Net assets	
Shareholders' equity	
Share capital	1,428,146
Capital surplus	1,338,146
Retained earnings	3,131,681
Treasury shares	(1,703)
Total shareholders' equity	5,896,272
Accumulated other comprehensive income	
Valuation difference on available-for-sale securities	5,937
Total accumulated other comprehensive income	5,937
Share acquisition rights	114,617
Total net assets	6,016,826
Total liabilities and net assets	7,023,969

(2) Consolidated Statements of Income and Comprehensive Income
Consolidated Statements of Income

(Thousands of yen)

	For the fiscal year ended October 31, 2025
Net sales	3,711,455
Cost of sales	1,623,978
Gross profit	2,087,476
Selling, general and administrative expenses	1,920,768
Operating profit	166,708
Non-operating income	
Interest income	251
Gain on sale of non-current assets	2,598
Refund of defined contribution pension plan	6,314
Compensation income	2,029
Miscellaneous income	4,462
Total non-operating income	15,657
Non-operating expenses	
Interest expenses	1,314
Loss on investments in investment partnerships	9,278
Foreign exchange losses	17
Loss on sale of non-current assets	854
Organization expenses	963
Compensation expenses	2,304
Other	9
Total non-operating expenses	14,741
Ordinary profit	167,624
Extraordinary income	
Gain on reversal of share acquisition rights	6,931
Total extraordinary income	6,931
Extraordinary losses	
Loss on exchange from property dividend	51,402
Loss on valuation of shares of subsidiaries and associates	13,306
Total extraordinary losses	64,708
Profit before income taxes	109,846
Income taxes - current	23,443
Income taxes - deferred	75,743
Total income taxes	99,186
Profit	10,659
Profit attributable to owners of parent	10,659

Consolidated Statements of Comprehensive Income

(Thousands of yen)

	For the fiscal year ended October 31, 2025
Profit	10,659
Other comprehensive income	
Valuation difference on available-for-sale securities	(4,416)
Total other comprehensive income	(4,416)
Comprehensive income	6,243
Comprehensive income attributable to	
Comprehensive income attributable to owners of parent	6,243

(3) Consolidated Statements of Changes in Equity

Fiscal year ended October 31, 2025 (from November 1, 2024 to October 31, 2025)

(Thousands of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	1,426,474	1,336,474	3,220,049	(1,703)	5,981,294
Changes during period					
Issuance of new shares	1,672	1,672			3,345
Dividends of surplus			(99,027)		(99,027)
Profit attributable to owners of parent			10,659		10,659
Net changes in items other than shareholders' equity					
Total changes during period	1,672	1,672	(88,367)	—	(85,022)
Balance at end of period	1,428,146	1,338,146	3,131,681	(1,703)	5,896,272

	Accumulated other comprehensive income		Share acquisition rights	Total net assets
	Valuation difference on available-for-sale securities	Total accumulated other comprehensive income		
Balance at beginning of period	10,353	10,353	45,453	6,037,101
Changes during period				
Issuance of new shares				3,345
Dividends of surplus				(99,027)
Profit attributable to owners of parent				10,659
Net changes in items other than shareholders' equity	(4,416)	(4,416)	69,163	64,747
Total changes during period	(4,416)	(4,416)	69,163	(20,274)
Balance at end of period	5,937	5,937	114,617	6,016,826

(4) Consolidated Statements of Cash Flows

(Thousands of yen)

	For the fiscal year ended October 31, 2025
Cash flows from operating activities	
Profit before income taxes	109,846
Depreciation	198,258
Amortization of long-term prepaid expenses	6,061
Amortization of lease deposits	13,575
Increase (decrease) in provision for bonuses for directors (and other officers)	4,221
Increase (decrease) in provision for share-based payments	6,777
Increase (decrease) in contract provision for loss	(9,499)
Interest income	(251)
Interest expenses	1,314
Gain on sale of non-current assets	(2,623)
Loss on sale of fixed assets	854
Loss (gain) on investments in investment partnerships	9,278
Organization expenses	963
Share-based payment expenses	3,955
Gain on reversal of share acquisition rights	(6,931)
Loss on exchange from dividend in kind	51,402
Loss (gain) on sale of shares of subsidiaries and associates	13,306
Decrease (increase) in trade receivables	(9,238)
Decrease (increase) in inventories	17,653
Increase (decrease) in trade payables	(31,177)
Other, net	40,442
Subtotal	418,190
Interest paid	(1,314)
Interest received	215
Income taxes paid	(91,974)
Income taxes refund	7,978
Net cash provided by (used in) operating activities	333,095
Cash flows from investing activities	
Purchase of property, plant and equipment	(43,190)
Proceeds from sale of property, plant and equipment	3,251
Purchase of intangible assets	(6,924)
Proceeds from sale of investment securities	49,992
Purchase of shares of subsidiaries and associates	(47,365)
Proceeds from sale of shares of subsidiaries and associates	6,000
Purchase of long-term prepaid expenses	(8,258)
Payments of leasehold and guarantee deposits	(1,000)
Proceeds from refund of leasehold and guarantee deposits	45,165
Other payments	(963)
Net cash provided by (used in) investing activities	(3,292)

(Thousands of yen)

For the fiscal year ended October 31, 2025	
Cash flows from financing activities	
Proceeds from issuance of shares	207
Net increase (decrease) in short-term borrowings	180,296
Repayments of lease liabilities	(20,571)
Dividends paid	(98,859)
Net cash provided by (used in) financing activities	61,071
Effect of exchange rate change on cash and cash equivalents	30
Net increase (decrease) in cash and cash equivalents	390,904
Cash and cash equivalents at beginning of period	4,320,915
Cash and cash equivalents at end of period	4,711,820